BT-474 Xenograft Model Service for Breast Cancer

The BT-474 xenograft model is a premier in vivo platform for evaluating therapeutics targeting HER2-positive luminal breast cancer, offering exceptional clinical translatability for hormone-sensitive tumor research. Alfa Cytology provides a specialized BT-474 xenograft model service, combining precise surgical techniques with advanced analytical readouts to accelerate your oncology drug discovery and validation programs.

Overview of BT-474 Xenograft Model for Breast Cancer

The BT-474 cell line is an essential tool in breast cancer research, derived from a human invasive ductal carcinoma. It is one of the few models that authentically represents the Luminal B subtype, characterized by a unique "triple-positive" receptor status: HER2-positive, Estrogen Receptor (ER)-positive, and Progesterone Receptor (PR)-positive.

As a xenograft model, BT-474 is particularly valued for its stable and high-level amplification of the ERBB2 (HER2) oncogene. Because its growth is highly dependent on estrogen, this model requires exogenous hormonal supplementation (such as 17β-estradiol pellets) to establish robust tumors in vivo. This hormone dependency makes it a sophisticated model for studying the cross-talk between HER2 signaling and ER pathways.

Fig 1. Investigation of the antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities elicited by H2Mab-77-mG2a-f. (Tanaka T, et al., 2024)

Cell Line Information: BT-474

Our Services

Workflow of BT-474 Xenograft Model Construction

The construction of a BT-474 xenograft model at Alfa Cytology follows a validated and highly controlled procedural workflow:

• Cell Culture & QC: BT-474 cells are expanded in vitro in specialized media supplemented with insulin. Strict STR authentication and mycoplasma testing are performed to ensure cell line integrity.
• Host Conditioning: Female immunocompromised mice are prepared. A critical step involves the surgical implantation of 17β-estradiol pellets to provide the necessary hormonal support for tumor growth.
• Inoculation: Cells are harvested and prepared in a Matrigel-containing suspension to maximize take rates. Inoculation is performed either subcutaneously or orthotopically into the mammary fat pad.
• Longitudinal Monitoring: We perform frequent tracking of tumor volume using digital calipers and monitor overall animal health to establish consistent growth kinetics.
• Randomization: Once tumors reach a target volume, animals are randomized into treatment groups to ensure statistical uniformity before dosing begins.

Fig 2. BT-474 Xenograft Model Construction Workflow

Case Study - BT-474 Xenograft Model Development

In a recent efficacy study, Alfa Cytology utilized the BT-474 model to validate a next-generation HER2-targeted ADC. By utilizing optimized orthotopic inoculation and precise estrogen dosing, we achieved a highly reproducible tumor growth curve across all experimental cohorts. The model showed a clear dose-dependent response to the ADC, with significant tumor regression observed.

Why Choose Alfa Cytology?

• Hormone Modeling Expertise: Proven success in maintaining estrogen-dependent models through specialized supplementation.
• Technical Precision: Expertise in orthotopic mammary fat pad injections to mimic the natural tumor microenvironment.
• Analytical Depth: Comprehensive endpoint services including IHC for receptor status and PK/PD profiling.
• Reliable Reproducibility: Standardized protocols designed to minimize variability and maximize data clarity.

Contact Us

Are you seeking to validate your novel HER2-targeted therapies in a high-fidelity luminal breast cancer model? Our scientific team is ready to provide the expertise and precision your program demands. Please reach out to us today to consult with our oncology experts on your study design, or contact us directly to receive a detailed quote.

For research use only. Not intended for any clinical use.